Work

Novel oral anticoagulants after gastric bypass surgery: Caveat emptor

Year: 2013

Type: article

Abstract: The Food and Drug Administration recently approved two new classes of oral anticoagulants: direct thrombin inhibitors, dabigatran etexilate and factor Xa inhibitors, apixaban and rivaroxaban. All these three drugs are for the treatment of nonvalvular atrial fibrillation with rivaroxaban also gaining approval for venous thromboembolism. Absorption of each drug is regulated by P-glycoprotein efflux transporters and is variable. The bioavailability of dabigatran etexilate is 7% with peak effect within two hours after administration. Apixaban has a 50% bioavailability with peak effect occurring 34 hours after administration and rivaroxaban has a bioavailability greater than 80% with peak effect occurring 24 hours after administration.

Source: International Journal of Case Reports and Images

DOI: 10.5348/ijcri-2013-11-406-le-20

Authors: Daniel J Lachant, Imran Uraizee, Rohit Gupta, Angelo J Pedulla

Institution: University of Rochester

Language: English

Topic: Atrial Fibrillation Management and Outcomes

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W1602679549

FWCI: 0.212

Cites: 6

Cited by: 10

Related to: 10